All aboard It didn’t take long for signs of Vertex’s trouble getting off the ground to become apparent. By March 2015, Vertex CEO Donald Croteau said that a variety of factors, including new ...

Importantly, Vertex increased the lower end of its full-year revenue guidance range, despite the intellectual property (IP) rights issues in Russia. The company now looks for 2025 revenue of ...

Vertex posted first-quarter adjusted earnings per share of $4.06, with revenue rising 3% year-over-year to $2.77 billion. Analysts surveyed by Visible Alpha were looking for $4.19 and $2.83 ...

Vertex Pharmaceuticals reported disappointing Q1 revenue and earnings. Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. Vertex reported Q1 revenue ...

Vertex Pharmaceuticals misses analyst estimates on the top and bottom lines in the first quarter. Vertex raises its full-year 2025 revenue guidance to a range of $11.85 billion to $12 billion ...

Vertex Pharmaceuticals missed Wall Street estimates for quarterly results on Monday due to lower-than-expected sales of its cystic fibrosis (CF) drug Trikafta, sending shares down 2.5% after the bell.

Vertex Solutions’ ITDs are utilized for the U.S. Air Force and Navy’s undergraduate pilot training enterprise, and the firm said they continue to demonstrate measurable performance outcomes.

Vertex completed enrollment and dosing in Parts A and B of the Phase 1/2 VX-264 (cells + device) study and the planned analysis at Day 90 for Part B. In Part B of the study, participants received ...

Vertex Pharmaceuticals (VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA). The company’s "first-in-class" suzetrigine pain pill ...

Vertex has priced Alyftrek at a list price of $370,269 per year, which is 7% higher than Trikafta’s annual wholesale acquisition cost of $346,048, according to a securities filing.

Vertex’s reconfiguration of the hydrocracker marks the first project by any operator taking on a flexible conventional-to-renewable unit conversion in recent years to return such a unit to its ...